237 related articles for article (PubMed ID: 29761525)
1. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
2. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
3. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.
Tan HL; Haffner MC; Esopi DM; Vaghasia AM; Giannico GA; Ross HM; Ghosh S; Hicks JL; Zheng Q; Sangoi AR; Yegnasubramanian S; Osunkoya AO; De Marzo AM; Epstein JI; Lotan TL
Mod Pathol; 2015 Mar; 28(3):446-56. PubMed ID: 25216229
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study.
Giannico GA; Ross HM; Lotan T; Epstein JI
Am J Surg Pathol; 2013 Sep; 37(9):1401-6. PubMed ID: 23774168
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
6. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
7. MAGI-2 in prostate cancer: an immunohistochemical study.
Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA
Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016
[TBL] [Abstract][Full Text] [Related]
8. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
9. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
11. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma.
Aubry MC; Roden A; Murphy SJ; Vasmatzis G; Johnson SH; Harris FR; Halling G; Knudson RA; Ketterling RP; Feldman AL
Mod Pathol; 2015 Mar; 28(3):359-66. PubMed ID: 25189640
[TBL] [Abstract][Full Text] [Related]
14. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
15. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.
Wang X; Boddicker RL; Dasari S; Sidhu JS; Kadin ME; Macon WR; Ansell SM; Ketterling RP; Rech KL; Feldman AL
Hum Pathol; 2017 Jun; 64():19-27. PubMed ID: 28153507
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
17. Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype.
Garcia FU; Haber MM; Chen X
Prostate; 2007 Nov; 67(15):1686-92. PubMed ID: 17879949
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
Hameed O; Sublett J; Humphrey PA
Am J Surg Pathol; 2005 May; 29(5):579-87. PubMed ID: 15832080
[TBL] [Abstract][Full Text] [Related]
19. A comparative immunohistochemistry study of diagnostic tools in salivary gland tumors: usefulness of mammaglobin, gross cystic disease fluid protein 15, and p63 cytoplasmic staining for the diagnosis of mammary analog secretory carcinoma?
Projetti F; Lacroix-Triki M; Serrano E; Vergez S; Barres BH; Meilleroux J; Delisle MB; Uro-Coste E
J Oral Pathol Med; 2015 Apr; 44(4):244-51. PubMed ID: 25040635
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
